Global Viscosupplementation Injection Market Strategic Research Report

Scope of the Report

The global Viscosupplementation Injection market size is predicted to grow from US$ 1,377 million in 2025 to US$ 2,003 million in 2032; it is expected to grow at a CAGR of 5.6% from 2026 to 2032.

Viscosupplementation is a medical procedure during which lubricating fluid is injected into a joint. Also called hyaluronic acid injections or hyaluronan injections, viscosupplementation is most commonly used to treat symptoms of symptoms of knee osteoarthritis. Viscosupplementation can significantly reduce pain while improving the mobility and function of the joint to make activities of daily living and even athletic or strenuous exercise less painful. Viscosupplementation is a procedure that involves injecting hyaluronic acid, a gel-like fluid, directly into the joint. Hyaluronic acid is found naturally in the synovial fluid surrounding the joints to reduce friction during movement. The injection goes into effect by lubricating the joint and assisting the synovial fluid to create more cushion. This works to reduce pain and improve the range of motion or the mobility of the joint.

The viscosupplementation injection market is driven by the rising prevalence of osteoarthritis, particularly among the aging population. As this treatment involves injecting hyaluronic acid into the joints to improve mobility and reduce pain, it offers a non-surgical alternative to managing osteoarthritis symptoms. The growing demand for minimally invasive procedures and the increasing awareness of joint health are also propelling the market forward. Additionally, advancements in injection technology and the development of next-generation viscosupplements are enhancing treatment outcomes, further supporting market growth.

However, the market faces challenges, including the high cost of viscosupplementation procedures, which can limit patient access, especially in developing regions. Moreover, the treatment's effectiveness may vary between patients, with some experiencing limited relief, which can reduce overall patient satisfaction. Competition from alternative treatments, such as corticosteroid injections and joint replacement surgeries, also presents a challenge to the market's expansion. Regulatory hurdles and reimbursement issues may further impact market growth, as insurers may not fully cover these treatments.

North America is the largest consumption place, with a consumption market share nearly 51% in 2023. Following North America, Asia-Pacific is the second largest consumption place with the consumption market share of 26%. Market competition is intense. Sanofi, Bioventus, Seikagaku, Anika Therapeutics, LG Chem, Ferring, etc. are the leaders of the industry. Top six company with about 43% market share.

This report presents a comprehensive overview of the global Viscosupplementation Injection market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Single Injection
• Three Injection
• Five Injection

Segment by Application

• Hospitals
• Clinics
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Viscosupplementation Injection market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hospitals, Clinics, Others evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact